{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:59:27Z","timestamp":1790351967461,"version":"4.1.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:p>We present the implementation of a service development framework for biologic biosimilars in patients with refractory pyoderma gangrenosum, developed following a review of available efficacy, safety and cost data. This approach enables earlier access to effective treatment while reducing reliance on prolonged conventional immunosuppression and associated potential healthcare burden. Our model provides a pragmatic framework to improve access to biologic therapies in rare inflammatory skin disease.<\/jats:p>","DOI":"10.1093\/ced\/llag232","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T11:34:57Z","timestamp":1780227297000},"page":"1914-1916","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of biologic treatments for pyoderma gangrenosum through a service development framework"],"prefix":"10.1093","volume":"51","author":[{"given":"Bayanne","family":"Olabi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dubois","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2210-6063","authenticated-orcid":false,"given":"Christiana","family":"Stavrou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ball","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Watson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hampton","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026092511021405900_llag232-B1","volume-title":"Rare Therapies and UK Regulatory Considerations","author":"Medicines and Healthcare products Regulatory Agency","year":"2025"},{"key":"2026092511021405900_llag232-B2","doi-asserted-by":"crossref","first-page":"e075863","DOI":"10.1136\/bmj-2023-075863","article-title":"Pyoderma gangrenosum","volume":"382","author":"Yeung","year":"2023","journal-title":"BMJ"},{"key":"2026092511021405900_llag232-B3","doi-asserted-by":"crossref","first-page":"h2958","DOI":"10.1136\/bmj.h2958","article-title":"UK Dermatology Clinical Trials Network\u2019s STOP GAP Team. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"},{"key":"2026092511021405900_llag232-B4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2013.05.028","article-title":"Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent","volume":"69","author":"Li","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2026092511021405900_llag232-B5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"2026092511021405900_llag232-B6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/1346-8138.17547","article-title":"Real-world safety and effectiveness of adalimumab in patients with pyoderma gangrenosum: interim analysis of a post-marketing observational study in Japan","volume":"52","author":"Yamamoto","year":"2025","journal-title":"J Dermatol"},{"key":"2026092511021405900_llag232-B7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1159\/000519320","article-title":"Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review","volume":"238","author":"Ben Abdallah","year":"2022","journal-title":"Dermatology"},{"key":"2026092511021405900_llag232-B8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ajd.14532","article-title":"Using biologics to reduce long-term corticosteroid use in pyoderma gangrenosum: real-world evidence from two centres","volume":"66","author":"Cascio Ingurgio","year":"2025","journal-title":"Australas J Dermatol"},{"key":"2026092511021405900_llag232-B9","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/ced\/llae153","article-title":"Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: results from a UK Dermatology Clinical Trials Network survey of dermatologists","volume":"49","author":"Jenkins","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026092511021405900_llag232-B10","author":"NHS England","year":"2025","journal-title":"Commissioning Framework for Best Value Biological Medicines"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag232\/68455617\/llag232.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1914\/68455617\/llag232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1914\/68455617\/llag232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:02:23Z","timestamp":1790348543000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/10\/1914\/8700156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":10,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,6,2]]},"published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag232","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,2]]}}}